Sanofi-Aventis S.A. ADR (SNY-Q) Quote - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low47.47

Day High47.93

Open:47.81

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Press & news

Latest News

Why Provention Bio Stock Skyrocketed 256% This Week

Motley Fool - Thu Mar 16, 3:56PM CDT

Motley Fool

Thu Mar 16, 3:56PM CDT

Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.

2 Top Biotech Stocks to Buy Right Now

Motley Fool - Wed Mar 15, 8:30AM CDT

Motley Fool

Wed Mar 15, 8:30AM CDT

These two companies are showering shareholders with market-topping payouts.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Business Wire - Mon Mar 13, 6:24PM CDT

Business Wire

Mon Mar 13, 6:24PM CDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the terms of the...

Latest Articles

Market movers: Stocks that saw action on Wednesday - and why

December 7, 2022

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

August 12, 2022

Leading U.S., European COVID-19 vaccine developers make pledge to uphold testing rigour

September 8, 2020

Investors bet $35-million on Montreal startup’s effort to revive failed class of weight-loss drugs

September 8, 2020

What every Canadian investor needs to know today

August 17, 2020

EU in advanced talks with Sanofi, GlaxoSmithKline for coronavirus vaccine

EU in talks with Moderna, BioNtech, CureVac to secure possible COVID-19 vaccines, sources say

Gordon Pape: As the search for a coronavirus vaccine intensifies, these five stocks are worth a look

Novartis to buy U.S. biotech The Medicines Co. for $9.7 billion

November 24, 2019

Before the Bell: Futures climb as Trump tweets Syria action could be ‘not soon at all’

Terry WeberApril 12, 2018

Canopy Growth among bidders for Spain’s Alcaliber: source

me and my money

This investor achieved an average 28% return within a year of every stock purchase. Here's how he did it

February 9, 2018

Data Update

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.